Kimberly Huber, PhD — University of Texas at Southwestern

Kimberly Huber, Ph.D.Evaluation of CamKII Dependent Regulation of mGluR5-Homer Scaffolds as a Potential Therapeutic for Fragile X Syndrome

with

Elena Nosyreva, PhD, Postdoctoral Fellow (2006)
Jennifer Ronesi, PhD, Postdoctoral Fellow (2007)
Tong Zang, PhD, Postdoctoral Fellow (2010-11)
Weirui Guo, PhD, Postdoctoral Fellow (2012 to 2013)

FRAXA thanks The Meadows Foundation for/of Texas for supporting these awards.

FRAXA Awards:
$45,000 in 2013
$45,000 in 2012
$45,000 in 2011
$45,000 in 2010
$51,000 in 2008
$49,000 in 2007
$50,000 in 2006
$50,000 in 2005
$63,300 in 2002
$31,000 in 2000

Dr. Huber made the original discovery of the mGluR Theory of Fragile X when she was a postdoctoral fellow in the lab of Dr. Mark Bear, with her first FRAXA grant in 2000.

 

 

DEVELOPMENTAL STUDY OF FMRP DEPENDENT SYNAPSE REGULATION IN FRAGILE X SYNDROME

Weirui Guo pictureby Weirui Guo, PhD, 6/11/2013

Enhanced metabotropic glutamate receptor subunit 5 (mGluR5) function is causally associated with the pathophysiology of Fragile X syndrome. Little is known about the molecular mechanisms that cause overactive mGluR5 in Fragile X. mGluR5 is less associated with its intracellular scaffolding protein, Homer, in Fragile X Syndrome mice (Fmr1 KO) which is linked with overactive mGluR5 and mGluR5 dysfunction in Fragile X. Drs. Guo and Huber are testing their hypothesis that enhanced phosphorylation of Homer by a specific Homer kinase, CaMKII, occurs in the brains of Fmr1 KO mice and leads to enhanced mGluR5 function and Fragile X phenotypes. These experiments will determine if Homer kinases, such as CamKII, are therapeutic targets for Fragile X Syndrome.

 

 

2011: Evaluation of CamKII Dependent Regulation of mGluR5-Homer Scaffolds as a Potential Therapeutic for Fragile X Syndrome

  –  with Tong Zang, PhD, Postdoctoral Fellow (2010-11)

by Tong Zang, PhD

Proper synapse maturation and elimination is crucial for the establishment of appropriate neural circuits that underlie sensory processing and cognition. Neuron of Fragile X patients as well as in the mouse model of Fragile X, Fmr1 KO mice, display more dendritic spines, the point of contact for excitatory synapses, as well as long and thin filopodia resembling immature spines. This suggests Fragile X Mental retardation protein (FMRP) has a role in promoting synapse maturation and elimination. Altered regulation of these processes in Fragile X Syndrome likely underlies many of the cognitive deficits associated with Fragile X Syndrome.

There is considerable evidence that synaptic plasticity and structure are altered in Fmr1 KO mice, but the mechanisms by which this occurs are unknown. Previously we demonstrated that acute postsynaptic expression of FMRP in CA1 pyramidal neurons in slice cultures elicits synapse elimination providing a direct cell autonomous role for FMRP in synapse elimination (Pfeiffer et al., 2007). We have gained important mechanistic insight into FMRP induced synapse elimination. The activity-dependent transcription factor, myocyte enhancer factor 2 (MEF2) also causes synapse elimination in neurons. We find that FMRP is required for MEF2 to elicit synapse elimination. Importantly, FMRP functions downstream of MEF2 activation and active MEF2 is required for FMRP to eliminate synapses (Pfeiffer, Zang et al., Neuron, 2010).

Most recently, we have observed developmental differences in the effects of acute FMRP expression on synaptic function. The developmental difference will give us a hint of how the disease occurs and proceeds. We hypothesize that these differences are due to developmental regulation of candidate transcription factors. We anticipate that our results will gain a better understanding of how FMRP regulates synapse development, why synapse density, maturation and connectivity are altered in Fragile X Syndrome and may lead to novel therapeutic strategies for the disease.

Our project has these aims:

Aim 1: Determine if there is a developmental switch in the effects of FMRP on dendritic spine structure and number.
Aim 2: Determine whether developmental regulation of MEF2 accounts for the switch of FMRP on synapse number.
Aim 3: Test MeCP2 as a transcription factor which regulates FMRP function in young neurons.

Results:

The team finds that the developmental switch of postsynaptic FMRP on synaptic function is controlled by MEF2 transcriptional activity.